Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy

Human epidermal growth factor receptor 2 (HER2)–positive breast cancers are currently treated with trastuzumab, an anti-HER2 antibody. About 30% of these tumors express a group of HER2 fragments collectively known as p95HER2. Our previous work indicated that p95HER2-positive tumors are resistant to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Natl Cancer Inst
Main Authors: Parra-Palau, Josep Lluís, Morancho, Beatriz, Peg, Vicente, Escorihuela, Marta, Scaltriti, Maurizio, Vicario, Rocio, Zacarias-Fluck, Mariano, Pedersen, Kim, Pandiella, Atanasio, Nuciforo, Paolo, Serra, Violeta, Cortés, Javier, Baselga, José, Perou, Charles M., Prat, Aleix, Rubio, Isabel T., Arribas, Joaquín
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Brief Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4271027/
https://ncbi.nlm.nih.gov/pubmed/25253614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/dju291
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados